马斯克脑机接口意念控制机械臂！演示者获得钢铁之吻，理论上可控制一切

Core Viewpoint - Neuralink is making significant advancements in brain-machine interface technology, focusing on enabling paralyzed patients to regain mobility and enhancing user interaction with technology through thought control [20][29]. Group 1: Technological Developments - Neuralink has successfully demonstrated thought-controlled robotic arm movements, showcasing the potential for direct brain control over devices [2][3]. - The company is implementing a "dual implant" strategy, where a second interface will be added to the spinal cord of the first human subject, aiming to create a "digital neural bridge" to bypass damaged biological pathways [8][9]. - Recent improvements have addressed issues with electrode stability, ensuring long-term signal reliability and shifting focus from unidirectional brain signal reading to complex bidirectional communication between the brain and spinal cord [9]. Group 2: User Experiences and Innovations - Users of Neuralink's technology are actively exploring additional applications beyond official functionalities, such as controlling everyday devices [10][11]. - A user named Brad Smith has successfully integrated a consumer webcam with the Neuralink system to overcome physical limitations caused by his condition, demonstrating the adaptability of the technology [12][15]. - Another user, Nathan Copeland, emphasizes the importance of combining the brain-machine interface with common devices to enhance daily life, illustrating the practical utility of the technology [19]. Group 3: Clinical Progress and Future Directions - Neuralink has achieved its first human implant in January 2024, marking a significant milestone in its clinical trials [21][29]. - The company has received FDA breakthrough device designations for projects aimed at restoring vision and aiding speech, indicating regulatory support for its innovative approaches [27][28]. - As of September 2024, Neuralink has completed implants for 12 subjects, with over 15,000 hours of device operation and no major rejection issues, paving the way for broader clinical applications [29].